In a groundbreaking advancement for cancer therapeutics, engineers at Duke University have unveiled an innovative platform that significantly enhances the intracellular delivery of large-molecule drugs using a method known as Sonoporation-assisted Precise Intracellular Nanodelivery, or SonoPIN. This cutting-edge technology leverages the synergy of ultrasound waves and microbubbles to facilitate the targeted entry of complex drugs like PROTACs (proteolysis-targeting chimeras) directly into cancer cells, catalyzing their self-destruction while sparing healthy cells.
The challenge with many promising oncological drugs, especially those large in molecular size such as PROTACs, lies in their limited cellular uptake. Conventional delivery methods frequently fail to ferry these drugs past the robust protective membrane of cells, resulting in suboptimal efficacy and troubling side effects caused by off-target activity. SonoPIN addresses this by employing engineered microbubbles that can be selectively attached to malignant cells through synthetic nucleic acid strands customized to recognize unique biochemical markers present exclusively on cancerous cell membranes.
When these microbubbles are subjected to controlled ultrasound waves, they undergo a phenomenon called sonoporation. In this process, the microbubbles collapse violently, generating mechanical forces — including high-velocity microjets and localized shock waves — directed at the adjacent cancer cells. These forces puncture transient nanoscale pores within the cellular membrane, temporarily increasing permeability without causing lasting damage. The pores provide gateways allowing the typically impermeable PROTAC molecules to pass effortlessly into the intracellular environment where they exert their therapeutic effects.
The intricacies of sonoporation remain a topic of ongoing research, but the prevailing model emphasizes its gentle yet precise mechanical nature. Unlike indiscriminate cellular disruption, sonoporation encourages the temporary opening of cell membranes in a way that maintains cell viability beyond short exposure. Notably, cells naturally reseal these pores rapidly, typically within minutes, thus mitigating prolonged vulnerability and minimizing unintended toxicity to surrounding tissues.
In experimental benchtop studies, the Duke team meticulously calibrated the ultrasound frequencies and intensity parameters to maximize drug delivery efficiency. They validated the method’s specificity by conjugating fluorescent markers to the PROTACs, revealing a sevenfold increase in intracellular accumulation when administered via the SonoPIN platform compared to conventional approaches. Remarkably, this led to a dramatic therapeutic outcome wherein 50% of targeted cancer cells were induced to self-destruct—a process known as apoptosis—while 99% of non-targeted healthy cells remained unharmed.
PROTAC technology itself represents a revolutionary shift in drug discovery and cancer treatment paradigms. Unlike traditional inhibitors, PROTACs function as molecular matchmakers, binding simultaneously to disease-causing proteins and E3 ubiquitin ligase enzymes. This recruitment triggers ubiquitination, a cellular signal designating the bound proteins for degradation by proteasomes, the cell’s “garbage disposal” machinery. In cancer cells, targeting proteins such as BRD4, crucial for uncontrolled proliferation, effectively dismantles their survival mechanisms and halts tumor progression.
Despite their transformative potential, the therapeutic deployment of PROTACs has been hindered by poor cell permeability and systemic toxicity risks due to off-target effects. This is especially critical as proteins like BRD4 are also vital to normal cell function. The SonoPIN platform’s ability to direct PROTAC uptake exclusively within cancer cells addresses this fundamental obstacle, highlighting its immense promise for clinical translation.
Looking ahead, the research team aims to extend their work beyond cellular models into in vivo applications using mouse tumor models. They are currently exploring the feasibility of administering PROTACs and microbubbles intravenously while employing focused ultrasound to precisely target tumor sites. This localized delivery strategy, if successful, could revolutionize cancer treatment by amplifying drug potency, reducing systemic exposure and side effects, and broadening the spectrum of deliverable therapeutics.
Another exciting aspect of SonoPIN is its mechanistic reliance on physical rather than biological uptake pathways. This distinction suggests an overarching versatility to deliver a wide array of therapeutic agents beyond PROTACs, including large biomolecular assemblies like gene-editing complexes or antibodies, which are traditionally challenging to transport efficiently into cells. Such versatility could open new frontiers in precision medicine and personalized oncology.
The research was financially supported by prominent agencies, including the National Institutes of Health and the National Science Foundation, underscoring the high-impact nature and translational relevance of the study. The findings were published in the prestigious journal Proceedings of the National Academy of Sciences with extensive contributions from multidisciplinary experts spanning mechanical engineering, molecular biology, and pharmaceutical sciences.
This innovation stands as a testament to the power of interdisciplinary collaboration in tackling formidable challenges in cancer therapeutics. By harnessing the interplay between acoustics, nanotechnology, and molecular pharmacology, SonoPIN holds the potential to catapult drug delivery methodologies into a new era where precision, efficacy, and safety coexist harmoniously to benefit patients worldwide.
Subject of Research: Cells
Article Title: SonoPIN Enables Precise, Noninvasive, and Efficient Intracellular Delivery of PROTACs.
News Publication Date: 13-Mar-2026
Web References: DOI: 10.1073/pnas.2534439123
Image Credits: Duke University
Keywords: Cancer medication, Medical treatments, Cancer, Ultrasound, Drug delivery systems, Pharmaceuticals
